$NVO, My thoughts on the drop, and where it's going

The primary reason for the crash was the company's February 2026 financial guidance, which shocked the market by projecting a 5% to 13% decline in sales and profit for the year, the first such contraction in nearly a decade. This was compounded just weeks later by a major clinical failure when their next-generation drug, CagriSema, failed to beat Eli Lilly's Zepbound in a head-to-head trial. Investors reacted violently to the realization that Novo is now fighting a two-front war: they are losing the clinical numbers game to Lilly’s more potent drugs, while simultaneously being forced into massive price cuts in the U.S. due to new government pricing deals and Most Favored Nation (MFN) policies. The company is heading toward a bridge year in 2026, where it will trade more like a traditional, low-multiple pharmaceutical value stock rather than a high-growth biotech. While the short-term sentiment is deeply negative, Novo is aggressively pivoting toward the Wegovy Pill (oral) and expanding into heart and kidney health to secure long-term insurance coverage that isn't dependent on "lifestyle" weight loss. If the company can successfully integrate its new manufacturing sites and stabilize its U.S. pricing by 2027, the stock is likely to bottom out at these levels and transition into a steady, dividend-paying recovery play for patient investors. If we see that, I'm buying and I'm bullish